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Abstract
A series of novel bichalcone analogs were synthesized and evaluated in lipopolysaccharide (LPS)-
activated microglial cells as inhibitors of nitric oxide (NO) and for in vitro anticancer activity
using a limited panel of four human cancer cell lines. All analogs inhibited NO production.
Compounds 4 and 11 exhibited optimal activity with IC50 values of 0.3 and 0.5 µM, respectively,
and were at least 38-fold better than the positive control. A mechanism of action study showed
that both compounds significantly blocked the nuclear translocation of NF-κB p65 and up-
regulation of iNOS at 1.0 µM. Compound 4 and three other analogs (3, 20, and 23) exerted
significant in vitro anticancer activity GI50 values ranging from 0.70~13.10 µM. A mode of action
study using HT-29 colon cancer cells showed that 23 acts by inducing apoptosis signaling.
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1. Introduction
Dietary flavonoids, commonly present in edible plants, are known to have beneficial effects,
such as antioxidative effects, tumor cell growth inhibitory activity, and apoptosis induction
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in cancer cell lines. Therefore, dietary flavonoids have attracted attention as
chemopreventive agents.1 Chalcones are the immediate precursors in the biosynthesis of
flavonoids, and their structure differs considerably from the other members of the flavonoid
family. Chalcones are reported with diverse biological activities including anti-
inflammatory, anti-malarial, anti-protozoal, anti-bacterial, nitric oxide inhibition, tyrosinase
inhibition, cytotoxic, anticancer, and anti-leishmanial activities.2–6 The bichalcones are well
represented in the Anacardiacea family. The Rhus genus is also a rich source for
biflavonoids and bichalcones. In general, naturally occurring bichalcones carry either C-O-C
or C-C linkage between the two chalcone units. Although natural bichalcones from Rhus
pyroides demonstrated varying degrees of cytotoxic activity against different cancer cell
lines, they showed more selectivity toward colon cancer cell lines, especially the HT29 and
HCT-116 cell lines.7
The Mannich base reaction is an important carbon-carbon bond-forming reaction in organic
synthesis, and it has been widely utilized in the synthesis of nitrogen-containing drugs,
natural products and biologically active compounds.8,9 Considering the pharmacological
importance of bichalcones, we synthesized a series of bichalcone analogs through the
piperazine Mannich base linkage with different substitutions in the B-ring of the chalcone
moiety. Target compounds were examined as inhibitors of nitric oxide (NO) production in
lipopolysaccharide (LPS)-activated microglial cells, which are important free radical-
producing cells in the central nervous system. Rapid production of reactive oxygen species
(ROS) by NADPH oxidase (NOX) and nitric oxide (NO) by NO synthase (NOS) can be
generated experimentally.10 Thus, we investigated the expression of iNOS protein and NF-
κB p65 (C) and p65 (N) in presence of bichalcone analogs. In addition, we further evaluated
the in vitro anticancer activity of the newly synthesized compounds against four human
cancer cell lines, and explored the mechanism of action of a selected compound (23) in the
HT-29 human colon adenocarcinoma cell line.
2. Chemistry
4-Hydroxyacetophenone (1) and 4-hydroxy-3-methoxyacetophenone (2) were reacted with
4-piperazinoacetophenone and paraformaldehyde in EtOH at 120 °C for 18–22 h to obtain
C-5 substituted Mannich base derivatives 1a and 2a, respectively (Scheme 1). Target
compounds 3–20 were obtained by the reaction of 1a or 2a with substituted aldehydes under
Claisen-Schmidt conditions using 30% KOH in MeOH at rt (Scheme 2). Compounds 1b and
1c were obtained by the reaction of 1 with pyrrole-2-carboxaldehyde and N-
methylpyrrole-2-carboxaldehyde, and 2b was obtained by the reaction of 2 with 3-
pyridinecarboxaldehyde under Claisen-Schmidt conditions. The target chalcones 21, 22, and
23 were prepared by the further reaction of 1b, 1c, and 2b with 4-piperazinoacetophenone
and paraformaldehyde in EtOH at 120 °C for 18–22 h (Scheme 3).
3. Results and discussion
Other laboratories have found that chalcone compounds can function as potent NF-κB
inhibitors11 and inhibit NO production.12 Based on these precedents, our new compounds
1a–23 were evaluated for inhibition of NOX-dependent ROS production and NOS-
dependent NO production in microglial cells as well as for 1,1-diphenyl-2-picrylhydrozyl
(DPPH) radical scavenging capacity. None of the compounds showed inhibition of NOX-
dependent ROS production or ability for direct radical-scavenging in a cell-free DPPH
solution. In contrast, 1a–23 were potent inhibitors of NO production in microglial cells with
IC50 values ranging from 0.3 to 30.5 µM, compared with L-nitroarginine methyl ester (L-
NAME) (IC50: 18.9 µM), a specific NOS inhibitor (Table 1).
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To summarize the initial structure-activity observations on the bichalcone analogs, we found
that a methoxy group at the C-3 position in the A-ring resulted in weaker NO production
inhibition activity compared with no substitution at this position, as seen with 1b (IC50: 15.9
µM) versus 1a (IC50: 6.6 µM). Concerning the B-ring, 3 and 4 with 2-pyridyl and 3-pyridyl
B-rings, respectively, showed improved activity with IC50 values of 1.4 and 0.3 µM,
respectively. Compounds 5 (IC50: 1.7 µM) and 6 (IC50: 1.9 µM) with 2-furanyl and 2-
thiophenyl B-rings, respectively, showed similar NO inhibition activity to that of 3. Adding
methyl groups at the C-3 or C-5 position of the thiophene or furan rings decreased the
compounds’ activity, as seen with 7 and 8. The introduction of a methoxy group at the C-4
position of the phenyl B-ring of 11 resulted in increased inhibition of NO production (IC50:
0.5 µM), while addition of chloro substituents on the B-ring as in 13 and 14 led to decreased
inhibition of NO production (IC50: 30.5 and 25.7 µM, respectively).
The influence of the most potent NO production inhibitors 4 and 11 on the iNOS protein
expression and NF-κB signaling pathway was further explored in LPS-activated BV2 cells
(Figure 1). Both compounds significantly blocked the nuclear translocation of NF-κB p65 at
1.0 µM concentration and decreased the iNOS protein expression. These results suggested
that 4 and 11 may target the NF-κB signaling pathway to block iNOS up-regulation, which
in turn suppresses the NO production.
Compounds 1a–23 were also evaluated for cytotoxicity against four human cancer cell lines,
DU145 (prostate cancer), A549 (non small cell lung cancer), KB (nasopharyngeal
carcinoma) and HCT-8 (ileocecal) (Table 2). It was found that the B-ring pyridyl moiety is
important for significant activity of the bichalcone analogs 3 (GI50: 1.08~1.26 µM), 4 (GI50:
1.40~2.19 µM), and 20 (GI50: 0.70~3.98 µM). Compound 23, bearing a single B-ring
pyridyl moiety, also showed activity, but with higher GI50 values (9.77 to 13.1 µM).
Compounds 21 and 22 with one pyrrole B-ring showed marginal cytotoxicity, and all the
other analogs tested were essentially inactive.
As shown in Figure 2A, 23 inhibited HT-29 cell viability in a dose-dependent manner.
HT-29 cells were then treated with 23 at a fixed concentration (30 µM), and cell viability
was determined over time up to three days. As shown in Figure 2B, 23 inhibited HT-29 cell
viability in a time-dependent manner. Figures 3A and B show the results from phase-
contrast microscopy of 23-treated HT-29 cells coupled with DAPI staining for the
occurrence of morphological changes and DNA condensation. Following treatment with 23
(30 and 50 µM), HT-29 cells exhibited nuclear shrinkage and chromatin condensation,
compared to the untreated control cells. To further investigate 23’s effect on the DNA of
HT-29 cells, we assessed the DNA fragmentation by terminal deoxynucleotidyl transferase-
mediated dUTP nick end labeling staining (TUNEL) coupled with flow cytometry. As
shown in Figure 4, 23 (30 µM) induced DNA fragmentation in HT-29 cells in a time-
dependent manner. This response is associated with apoptosis, so the effects of 23 on the
signaling pathway were investigated.
The activities of caspase-3, -8, and -9 in 23-treated HT-29 cells detected by colorimetric
enzymatic assay are shown in Figure 5A. All of the active caspases were detected after 24 h
treatment with 23. To verify the involvement of caspase-3, -8, and -9 in 23-induced
apoptosis of HT-29 cells, inhibitors of each caspase (caspase-3, Z-DEVE-FMK; caspase-8,
Z-IETD-FMK; caspase-9, Z-LEHD-FMK) were used. The results shown in Figure 5B are
consistent with 23 inducing apoptosis through the activation of caspase-3, -8, and -9. The
relative levels of 12 key apoptosis-associated protein levels in 23-treated HT-29 cells were
then analyzed using Western Blot Analysis. Compound 23 increased the protein expression
of Fas/CD95, FADD (Figure 6A), cytosolic cytochrome c, Apaf-1, AIF, Endo G (Figure
6B), caspase-3 (Figure 6C), Bax (Bcl2-associated X protein), and t-Bid (Fig 6D), and
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decreased the protein levels of pro-caspase-8, pro-caspase-9 (Figure 6C) and Bcl-2 (Figure
6D). The analysis results suggested that 23 induces apoptosis in HT-29 cells via both death
receptor (Fas/CD95) and mitochondrial-dependent pathways.13–15 The effects of 23 on the
proteins analyzed and the interactions of these proteins within the Fas/CD95 and
mitochondrial-dependent pathways are shown graphically on the left and right sides,
respectively, of Figure 7.
In summary, a series of bichalcones with a piperazine Mannich base linkage was prepared
and evaluated for inhibition of NO production in microglial cells and for in vitro anticancer
activity. Compounds 4 and 11 were potent inhibitors of cellular NO production in LPS-
activated microglial cells, likely indirectly via blockade of NF-κB p65 nuclear translocation.
Several bichalcone analogs, including 4 as well as 3, 20, and 23, with a signature pyridyl
moiety also showed significant activity against human tumor cell replication. Exploration of
the mechanism of action showed that 23 likely acted via the Fas/CD95 apoptosis signaling
pathway.
4. Experimental Section
4.1. Materials and Methods
Melting points were determined using a Yanagimoto MP-S3 micro-melting point apparatus
and are uncorrected. IR spectra were determined on a Shimadzu FT-IR Prestige 21
spectrophotometer. 1H and 13C NMR spectra were recorded on a Bruker Avance 300
spectrometer, using tetramethylsilane (TMS) as internal standard; all chemical shifts are
reported in parts per million (ppm, δ). FABMS and HRFABMS spectra were obtained on a
JEOL JMS-700 mass spectrometer. Column chromatography was performed on silica gel
(70–230 mesh, 230–400 mesh). TLC was conducted on precoated Kieselgel 60 F254 plates
(Merck), and the spots were detected by UV. Elemental analyses were determined by
Elementer Vario EL III and gave combustion values for C, H, N and S. Concentration of the
reaction solutions involved the use of rotary evaporator under reduced pressure. All other
chemicals were obtained from Aldrich, Inc. Dimethyl sulfoxide (DMSO), 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 4',6-diamidino-2-
phenylindole (DAPI), Tris-HCl and Triton X-100 were obtained from Sigma Chemical Co.
(St. Louis, MO, USA). Caspase-8 inhibitor, z-Ile-Glu-Thr-Asp-fluoromethyl ketone (Z-
IETD-FMK), Caspase-9 inhibitor, z-Leu-Glu-His-Asp-fluoromethyl ketone (Z-LEHD-
FMK), Caspase-3 inhibitor z-Asp-Met-Gln-Asp-fluoromethyl ketone (Z-DEVD-FMK)
(R&D, USA) were dissolved in DMSO and diluted in cell culture medium before use. RPMI
1640, penicillin-streptomycin, trypsin-EDTA, fetal bovine serum (FBS), and glutamine were
obtained from Gibco BRL (Invitrogen, Grand Island, NY).
4.2. General procedure for the synthesis of Mannich bases of acetophenones
To a solution of hydroxy-substituted acetophenone and paraformaldehyde in EtOH (75 mL)
was added 4-piperazinoacetophenone at rt as per reported earlier literature.16–19 Then the
resulting mixture was heated to reflux for 18–22 h at 120 °C. On completion, the reaction
mixture was concentrated under reduced pressure and the crude product was purified by
column chromatography to yield the ortho substituted Mannich base in good yield (Scheme
1).
4.2.1. 1-(4-(4-(5-Acetyl-2-hydroxybenzyl)piperazin-1-yl)phenyl)ethanone (1a)—
Compound 1 (13.6 g, 100 mmol), paraformaldehyde (3.0 g, 100 mmol) and 4-
piperizinoacetophenone (20.4 g, 100 mmol) were treated as described above. The crude
product was purified by CC eluting with (i-Pr)2O/MeOH (9:1) to yield 1a (colorless
crystalline solid, 24.5 g, 69.6%), mp 146–148 °C. IR (neat) 3005, 2711, 1666, 1597, 1519,
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1442, 1357, 1284, 1238, 1195, 1118, 1002, 925, 825, 756, 690, 563, 513 cm−1.1H NMR
(CDCl3, 300 MHz): δ 7.87 (3H, d, J = 8.7 Hz), 7.74 (1H, s), 6.86 (3H, d, J = 8.7 Hz), 3.86
(2H, s), 3.47 (4H, s), 2.77 (4H, s), 2.54 (3H, s), 2.52 (3H, s).13C NMR (CDCl3, 75 MHz): δ
196.6, 196.4, 162.3, 153.6, 130.4, 130.3 (x2), 129.4, 129.1, 128.2, 120.5, 116.0, 113.8 (x2),
61.0, 52.0 (x2), 47.2 (x2), 26.2, 26.1.FABMS, m/z (% rel. intensity): 353 (100) [M+H]+, 352
(76), 351 (39), 205 (27), 204 (15), 203 (26), 177 (14), 174 (11), 162 (23), 154 (13), 149 (37),
148 (12), 136 (11).HRFABMS m/z calcd for C21H25O3N2, 353.1865; found, 353.1866.
Elemental Analysis: calcd C, 71.57; H, 6.86; N, 7.95; found, C, 71.08; H, 6.88; N, 7.80.
4.2.2. 1-(4-(4-(5-Acetyl-2-hydroxy-3-methoxybenzyl)piperazin-1-
yl)phenyl)ethanone (2a)—Compound 2 (8.3 g, 50 mmol), paraformaldehyde (1.5 g, 50
mmol) and 4-piperizinoacetophenone (10.2 g, 50 mmol) were treated as described above.
The crude product was purified by CC eluting with (i-Pr)2O/MeOH (7:3) to yield 2a
(colorless crystalline solid, 14.5 g, 76%), mp 130–132 °C. IR (neat) 2831, 1666, 1597, 1516,
1489, 1450, 1411, 1537, 1296, 1234, 1141, 1083, 1002, 956, 921, 821, 752, 594, 559
cm−1.1H NMR (CDCl3, 300 MHz): δ 7.83 (2H, d, J = 9.0 Hz), 7.44 (1H, s), 7.28 (1H, s),
6.83 (2H, d, J = 9.0 Hz), 3.89 (3H, s), 3.81 (2H, s), 3.36 (4H, s), 2.72 (4H, s), 2.51 (3H, s),
2.48 (3H, s). 13C NMR (CDCl3, 75 MHz): δ 196.4, 196.3, 153.5, 151.8, 147.8, 130.2 (x2),
128.7, 128.1, 122.5, 119.8, 113.7 (x2), 110.4, 60.7, 55.8, 51.9 (x2), 47.2 (x2), 25.9 (x2).
FABMS, m/z (% rel. intensity): 383 (100) [M+H]+, 382 (75), 381 (28), 307 (12), 217 (12),
207 (13), 205 (25), 204 (11), 203 (22), 179 (40), 162 (20), 155 (17), 154 (67), 138 (20), 137
(41), 136 (51), 120 (11), 107 (16), 91 (11), 89 (13), 77 (11).HRFABMS m/z calcd for
C22H27O4N2, 383.1971; found, 383.1968. Elemental Analysis: calcd C, 69.09; H, 6.85; N,
7.32; found, C, 68.42; H, 7.07; N, 7.37.
4.3. General procedure for the synthesis of bichalcones through the piperazine Mannich
base linkage
The general synthetic strategy employed to prepare the bichalcones through the piperazine
Mannich base linkage analogs were based on the Claisen-Schmidt condensation. As shown
in Scheme 2, a series of 23 bichalcones were prepared by base-catalyzed condensation of
substituted Mannich bases of acetophenones with appropriate aldehydes in MeOH. To a
stirred reaction mixture at 0 °C was added a 30% solution of KOH (40 mL) dropwise over
30 min. The reaction mixture was kept at rt for 24 h, then diluted with water and extracted
with EtOAc. Pure target compounds were obtained by silica gel column chromatography
(cc) of the residue eluting with various solvent mixtures as indicated below. The structures
of all the 23 bichalcones through the piperazine Mannich base linkage analogs were
established on the basis of IR, 1H, 13CNMR, FABMS and HRFABMS.
4.3.1. (E)-1-(4-Hydroxy-3-((4-(4-((E)-3-(pyridin-2-yl)acryloyl)phenyl)piperazin-1-
yl)methyl)phenyl)-3-(pyridin-2-yl)prop-2-en-1-one (3)—Compound 1a (704 mg, 2.0
mmol) and 2-pyridinecarboxaldehyde (428 mg, 4.0 mmol) were treated as described above.
The crude product was purified by CC eluting with hexanes/EtOAc (1:1) to yield 3 (pale
yellow solid, 680 mg, 64%), mp 59–61 °C. IR (neat) 2874, 1657, 1608, 1589, 1522, 1468,
1432, 1387, 1329, 1225, 1193, 1111, 1027, 993, 927, 830, 782, 661, 569 cm−1.1H NMR
(DMSO-d6, 300 MHz): δ 8.67 (2H, s), 8.14 (2H, dd, J = 15.3, 15.3 Hz), 7.99 (4H, t, J = 5.7
Hz), 7.87 (4H, s), 7.66 (2H, dd, J = 15.3, 15.3 Hz), 7.41 (2H, d, J = 3.9 Hz), 7.03 (3H, dd, J
= 8.4 Hz), 3.75 (2H, s), 3.43 (4H, s), 2.63 (4H, s). 13C NMR (DMSO-d6, 75 MHz): δ 187.3,
186.5, 161.7, 153.8, 153.1, 152.9, 149.9 (x2), 141.8, 141.3, 137.1 (x2), 130.9, 130.6 (x2),
129.9, 128.7, 126.9, 125.3, 125.1, 124.8, 124.6 (x2), 124.4, 123.0, 115.5, 113.3 (x2), 57.2,
51.9 (x2), 46.4 (x2).FABMS, m/z (% rel. intensity): 531 (11) [M+H]+, 530 (8), 481 (1), 460
(1), 437 (1), 391 (4), 307 (10), 294 (14), 292 (10), 291 (8), 251 (9), 239 (13), 238 (19), 210
(4), 207 (5), 195 (5), 194 (5), 180 (6), 167 (9), 155 (25), 154 (100), 152 (9), 149 (17), 139
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(14), 138 (35), 137 (65), 136 (87), 132 (45), 124 (11), 120 (15), 107 (40), 91 (26), 90 (32),
89 (51), 77 (44).
HRFABMS m/z calcd for C33H31O3N4, 531.2396; found, 531.2397. Elemental Analysis:
calcd C, 74.70; H, 5.75; N, 10.56; found, C, 74.52; H, 5.92; N, 10.34.
4.3.2. (E)-1-(4-Hydroxy-3-((4-(4-((E)-3-(pyridin-3-yl)acryloyl)phenyl)piperazin-1-
yl)methyl)phenyl)-3-(pyridin-3-yl)prop-2-en-1-one (4)—Compound 1a (704 mg, 2.0
mmol) and 3-pyridinecarboxaldehyde (428 mg, 4.0 mmol) were treated as described above.
The crude product was purified by CC eluting with CHCl3/MeOH (9:1) to yield 4 (pale
yellow solid, 720 mg, 68%), mp 69–71 °C. IR (neat) 3420, 2835, 1654, 1600, 1527, 1419,
1346, 1307, 1284, 1226, 1192, 1122, 1026, 995, 925, 806, 736, 702, 628 cm−1.1H NMR
(DMSO-d6, 300 MHz): δ 9.00 (2H, d, J = 4.5 Hz), 8.60 (2H, s), 8.33 (2H, d, J = 9.0 Hz),
8.06 (2H, d, J = 15.9 Hz), 8.05 (4H, m), 7.70 (2H, dd, J = 15.6, 15.6 Hz), 7.48 (2H, t, J = 3.9
Hz), 7.04 (2H, d, J = 8.4 Hz), 6.93 (1H, d, J = 9.0 Hz), 3.77 (2H, s), 3.44 (4H, s), 2.64 (4H,
s). 13C NMR (DMSO-d6, 75 MHz): δ 186.7, 186.3, 161.8, 158.5, 152.8, 149.3, 148.6, 148.2,
139.1, 138.2, 137.1, 136.6, 135.0, 132.7, 131.7, 131.3, 130.8 (x2), 128.8, 127.8, 124.9,
124.6, 124.5, 124.4, 116.4, 115.7, 113.9 (x2), 53.6, 50.5 (x2), 43.8 (x2).FABMS, m/z (% rel.
intensity): 531 (5) [M+H]+, 307 (35), 289 (18), 280 (8), 165 (8), 156 (9), 155 (48), 154
(100), 153 (11), 152 (15), 150 (6), 139 (21), 138 (59), 137 (98), 136 (96), 124 (15), 121 (13),
120 (23), 108 (15), 107 (45), 106 (13), 105 (14), 91 (25), 90 (31), 89 (43), 77 (34), 65
(12).HRFABMS m/z calcd for C33H31O3N4, 531.2396; found, 531.2393. Elemental
Analysis: calcd C, 74.70; H, 5.75; N, 10.56; found, C, 74.08; H, 5.92; N, 10.34.
4.3.3. (E)-3-(Furan-2-yl)-1-(4-(4-(5-((E)-3-(furan-2-yl)acryloyl)-2-
hydroxybenzyl)piperazin-1-yl)phenyl)prop-2-en-1-one (5)—Compound 1a (704
mg, 2.0 mmol) and 2-furaldehyde (384 mg, 4.0 mmol) were treated as described above. The
crude product was purified by CC eluting with hexanes/EtOAc (7:3) to yield 5 (pale yellow
solid, 780 mg, 77%), mp 169–171 °C. IR (neat) 3417, 2920, 1651, 1600, 1550, 1527, 1473,
1388, 1350, 1280, 1230, 1192, 1111, 1018, 925, 817, 744, 644 cm−1.1H NMR (CDCl3, 300
MHz): δ 8.00 (2H, d, J = 9.0 Hz), 7.94 (1H, s), 7.81 (1H, s), 7.58 (2H, dd, J = 15.0, 15.0
Hz), 7.51 (2H, m), 7.46 (2H, d, J = 15.6 Hz), 6.91 (3H, d, J = 9.0 Hz), 6.68 (2H, d, J = 4.5
Hz), 6.50 (2H, s), 3.86 (2H, s), 3.44 (4H, s), 2.76 (4H, s). 13C NMR (CDCl3, 75 MHz): δ
187.8, 187.5, 162.4, 153.6, 151.9, 151.8, 144.6, 144.5, 130.5 (x2), 130.4, 130.0, 129.9 (x2),
129.5, 129.0, 120.8, 119.2, 119.0, 116.2, 115.8, 115.5, 114.0 (x2), 112.6, 112.5, 61.1, 52.1
(x2), 47.3 (x2). FABMS, m/z (% rel. intensity): 509 (24) [M+H]+, 508 (11), 307 (27), 289
(14), 283 (9), 240 (7), 227 (7), 155 (36), 154 (100), 153 (9), 152 (13), 147 (8), 139 (17), 138
(42), 137 (82), 136 (100), 135 (11), 124 (11), 121 (23), 120 (18), 115 (9), 108 (10), 107 (33),
106 (11), 105 (12), 91 (24), 90 (26), 89 (30), 78 (12), 77 (23), 73 (20).HRFABMS m/z calcd
for C31H29O5N2, 509.2076; found, 509.2073. Elemental Analysis: calcd C, 73.21; H, 5.55;
N, 5.51; found, C, 72.97; H, 5.44; N, 5.32.
4.3.4. (E)-1-(4-Hydroxy-3-((4-(4-((E)-3-(thiophen-2-
yl)acryloyl)phenyl)piperazin-1-yl)methyl)phenyl)-3-(thiophen-2-yl)prop-2-en-1-
one (6)—Compound 1a (704 mg, 2.0 mmol) and 2-thiophenecarboxaldehyde (448 mg, 4.0
mmol) were treated as described above. The crude product was purified by CC eluting with
hexanes/EtOAc (1:1) to yield 6 (pale yellow solid, 750 mg, 69%), mp 126–128 °C. IR (neat)
2874, 1648, 1600, 1511, 1450, 1426, 1365, 1285, 1232, 1190, 1125, 1105, 1028, 998, 925,
817, 708, 657, 566 cm−1.1H NMR (CDCl3, 300 MHz): δ 7.97 (2H, d, J = 9.0 Hz), 7.86 (2H,
d, J = 15.0 Hz), 7.75 (2H, s), 7.35 (2H, d, J = 15.0 Hz), 7.32 (3H, m), 7.07 (2H, s), 6.91 (4H,
d, J = 8.1 Hz), 3.87 (2H, s), 3.45 (4H, s), 2.78 (4H, s). 13C NMR (CDCl3, 75 MHz): δ 187.4
(x2), 153.5, 140.6, 140.5, 136.3, 135.8, 131.7, 131.5, 130.5 (x3), 130.3, 129.8, 129.4, 128.8,
128.4, 128.2 (x2), 128.1 (x2), 120.6, 120.4, 113.9 (x3), 61.0, 52.0 (x2), 47.2 (x2).FABMS,
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m/z (% rel. intensity): 541 (12) [M+H]+, 540 (9), 523 (2), 505 (3), 447 (21), 446 (12), 431
(8), 391 (6), 300 (6), 299 (20), 297 (16), 281 (11), 256 (17), 255 (5), 243 (11), 242 (12), 221
(12), 217 (11), 207 (15), 189 (13), 167 (15), 165 (16), 155 (20), 154 (67), 152 (19), 150 (14),
149 (48), 137 (66), 136 (84), 115 (23), 111 (18), 107 (46), 97 (34), 95 (50), 91 (67), 90 (42),
89 (51), 81 (59), 73 (100), 71 (40), 67 (45), 55 (87).HRFABMS m/z calcd for
C31H29O3N2S2, 541.1620; found, 541.1617. Elemental Analysis: calcd C, 68.86; H, 5.22; N,
5.18; S, 11.86; found, C, 68.36; H, 5.52; N, 5.45; S, 11.15.
4.3.5. (E)-1-(4-Hydroxy-3-((4-(4-((E)-3-(3-methylthiophen-2-yl)acryloyl)phenyl)-
piperazin-1-yl)methyl)phenyl)-3-(3-methylthiophen-2-yl)prop-2-en-1-one (7)—
Compound 1a (704 mg, 2.0 mmol) and 3-methyl-2-thiophenecarboxaldehyde (504 mg, 4.0
mmol) were treated as described above. The crude product was purified by CC eluting with
hexanes/EtOAc (7:3) to yield 7 (pale yellow solid, 860 mg, 76%), mp 179–181 °C. IR (neat)
2875, 1648, 1600, 1516, 1493, 1452, 1384, 1288, 1220, 1189, 1110, 1034, 926, 820, 752,
629 cm−1.1H NMR (CDCl3, 300 MHz): δ 8.04 (1H, d, J = 3.9 Hz), 7.97 (2H, d, J = 15.0
Hz), 7.96 (2H, d, J = 9.0 Hz), 7.81 (1H, s), 7.29 (2H, d, J = 9.0 Hz), 7.28 (2H, d, J = 15.0
Hz), 6.90 (5H, m), 3.90 (2H, s), 3.46 (4H, s), 2.80 (4H, s), 2.38 (6H, s). 13C NMR (CDCl3,
75 MHz): δ 187.8, 187.5, 162.2, 153.4, 142.3, 142.0, 134.7 (x2), 134.5, 134.3, 131.3 (x2),
130.4 (x2), 130.3, 130.0, 129.9, 129.0, 126.6, 120.5, 119.6, 119.4, 116.2, 113.9 (x2), 60.8,
52.0 (x2), 47.1 (x2), 14.2 (x2). FABMS, m/z (% rel. intensity): 569 (29) [M+H]+, 568 (18),
553 (2), 461 (2), 445 (10), 313 (23), 312 (9), 311 (20), 309 (8), 307 (10), 281 (11), 270 (17),
258 (11), 257 (17), 207 (15), 189 (12), 165 (10), 155 (23), 154 (89), 152 (19), 151 (54), 149
(18), 147 (30), 138 (30), 137 (56), 136 (100), 107 (41), 105 (24), 91 (36), 90 (36), 89 (48),
77 (48), 73 (78), 71 (19), 69 (31), 57 (38), 55 (38).HRFABMS m/z calcd for C33H33O3N2S2,
569.1933; found, 569.1931. Elemental Analysis: calcd C, 69.69; H, 5.67; N, 4.93; S, 11.58;
found, C, 69.48; H, 5.71; N, 4.90; S, 11.46.
4.3.6. (E)-1-(4-Hydroxy-3-((4-(4-((E)-3-(5-methylfuran-2-
yl)acryloyl)phenyl)piperazin-1-yl)methyl)phenyl)-3-(5-methylfuran-2-yl)prop-2-
en-1-one (8)—Compound 1a (704 mg, 2.0 mmol) and 5-methyl-2-furaldehyde (440 mg,
4.0 mmol) were treated as described above. The crude product was purified by CC eluting
with hexanes/EtOAc (7:3) to yield 8 (pale yellow solid, 750 mg, 70%), mp 94–96 °C. IR
(neat) 3390, 2873, 1651, 1600, 1527, 1446, 1350, 1222, 1192, 1118, 1022, 802, 732, 671,
617 cm−1.1H NMR (CDCl3, 300 MHz): δ 8.01 (2H, d, J = 9.0 Hz), 7.97 (1H, dd, J = 8.4, 2.1
Hz), 7.82 (1H, d, J = 2.1 Hz), 7.53 (2H, dd, J = 15.3, 15.3 Hz), 7.38 (2H, dd, J = 15.3, 15.3
Hz), 6.92 (2H, d, J = 9.0 Hz), 6.90 (1H, d, J = 3.3 Hz), 6.59 (2H, dd, J = 3.3, 6.0 Hz), 6.12
(2H, t, J = 3.3 Hz), 3.88 (2H, s), 3.57 (4H, s), 2.77 (4H, s), 2.40 (6H, s). 13C NMR (CDCl3,
75 MHz): δ 187.8, 187.5, 162.1, 155.5, 155.3, 153.4, 150.5, 150.4, 130.4 (x2), 130.2, 130.1,
130.0, 129.7, 129.6, 129.2, 120.7, 117.7, 117.5, 117.4, 117.2, 116.0, 113.9 (x2), 109.2,
109.1, 61.1, 52.1 (x2), 47.3 (x2), 13.9 (x2). FABMS, m/z (% rel. intensity): 537 (61) [M
+H]+, 536 (39), 535 (13), 429 (13), 307 (22), 297 (28), 296 (13), 295 (21), 254 (19), 240
(14), 155 (26), 154 (100), 139 (11), 138 (28), 137 (52), 136 (73), 135 (50), 120 (12), 107
(26), 91 (12), 90 (14), 89 (20), 77 (19).HRFABMS m/z calcd for C33H33O5N2, 537.2389;




yl)prop-2-en-1-one (9)—Compound 1a (704 mg, 2.0 mmol) and N-methylpyrrole-2-
carboxaldehyde (436 mg, 4.0 mmol) were treated as described above. The crude product
was purified by CC eluting with hexanes/EtOAc (7:3) to yield 9 (pale yellow solid, 780 mg,
73%), mp 90–92 °C. IR (neat) 2877, 1642, 1599, 1525, 1480, 1416, 1383, 1336, 1279, 1223,
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1192, 1111, 1059, 1033, 998, 927, 825, 744, 627, 605, 573 cm−1.1H NMR (DMS0-d6, 300
MHz): δ 7.99 (2H, d, J = 8.4 Hz), 7.98 (2H, s), 7.65 (2H, dd, J = 15.0, 15.0 Hz), 7.51 (2H, d,
J = 15.0 Hz), 7.02 (6H, m), 6.90 (1H, d, J = 9.0 Hz), 6.16 (2H, d, J = 2.7 Hz), 3.76 (6H, s),
3.75 (2H, s), 3.40 (4H, s), 2.63 (4H, s). 13C NMR (DMS0-d6, 75 MHz): δ 186.6, 186.0,
161.1, 153.4, 131.1, 130.5 (x2), 130.1 (x2), 129.9, 129.8, 129.6, 129.5, 128.2, 128.0, 127.9,
122.6, 116.2, 116.0, 115.3, 113.4 (x2), 112.7, 112.5, 109.2, 109.1, 57.7, 51.9 (x2), 46.7 (x2),
33.9 (x2). FABMS, m/z (% rel. intensity): 535 (9) [M+H]+, 428 (7), 307 (5), 296 (22), 295
(9), 294 (21), 253 (19), 241 (13), 240 (25), 239 (14), 189 (18), 155 (16), 154 (68), 153 (13),
149 (17), 147 (14), 137 (47), 136 (68), 134 (100), 133 (18), 131 (10), 121 (13), 120 (20),
107 (42), 106 (37), 105 (19), 91 (34), 90 (34), 89 (54), 81 (24), 78 (32), 77 (62), 73 (54), 71
(16), 69 (19), 65 (23), 63 (23), 57 (34), 55 (35).HRFABMS m/z calcd for C33H35O3N4,
535.2709; found, 535.2709. Elemental Analysis: calcd C, 74.13; H, 6.41; N, 10.48; found,
C, 73.97; H, 6.55; N, 10.14.
4.3.8. (E)-1-(4-(4-(5-Cinnamoyl-2-hydroxybenzyl)piperazin-1-yl)phenyl)-3-
phenylprop-2-en-1-one (10)—Compound 1a (704 mg, 2.0 mmol) and benzaldehyde
(424 mg, 4.0 mmol) were treated as described above. The crude product was purified by CC
eluting with hexanes/EtOAc (8:2) to yield 10 (pale yellow solid, 625 mg, 59%), mp 179–181
°C. IR (neat) 3414, 2831, 1651, 1600, 1527, 1492, 1446, 1346, 1280, 1226, 1188, 1033, 995,
925, 825, 767, 736, 694 cm−1.1H NMR (CDCl3, 300 MHz): δ 8.01 (2H, d, J = 9.0 Hz), 7.96
(1H, dd, J = 9.0, 1.8 Hz), 7.80 (2H, dd, J = 15.6, 15.6 Hz), 7.82 (1H, s), 7.65 (4H, d, J = 6.0
Hz), 7.55 (2H, d, J = 15.6 Hz), 7.40 (6H, m), 6.93 (3H, d, J = 9.0 Hz), 3.88 (2H, s), 3.45
(4H, s), 2.77 (4H, s). 13C NMR (CDCl3, 75 MHz): δ 188.4, 188.1, 162.4, 153.6, 143.8,
143.4, 135.2, 135.0, 130.6 (x2), 130.4, 130.3, 130.1, 129.9, 129.0 (x3), 128.8 (x2), 128.4
(x2), 128.3 (x3), 121.8, 121.7, 120.8, 116.2, 114.0 (x2), 61.1, 52.1 (x2), 47.3 (x2). FABMS,
m/z (% rel. intensity): 529 (11) [M+H]+, 308 (8), 307 (33), 293 (7), 289 (19), 189 (5), 178
(5), 166 (7), 165 (11), 156 (9), 155 (47), 154 (100), 153 (11), 152 (16), 139 (22), 138 (58),
137 (98), 136 (92), 131 (14), 124 (16), 121 (22), 120 (24), 115 (10), 108 (15), 107 (46), 105
(16), 91 (27), 90 (32), 89 (43), 79 (12), 77 (37), 65 (12), 63 (11).HRFABMS m/z calcd for
C35H33O3N2, 529.2491; found, 529.2494. Elemental Analysis: calcd C, 9.52; H, 6.10; N,
5.30; found, C, 78.47; H, 6.16; N, 5.04.
4.3.9. (E)-1-(4-Hydroxy-3-((4-(4-((E)-3-(4-
methoxyphenyl)acryloyl)phenyl)piperazin-1-yl)methyl)phenyl)-3-(4-
methoxyphenyl)prop-2-en-1-one (11)—Compound 1a (704 mg, 2.0 mmol) and 4-
methoxybenzaldehyde (544 mg, 4.0 mmol) were treated as described above. The crude
product was purified by CC eluting with hexanes/EtOAc (7:3) to yield 11 (pale yellow solid,
720 mg, 61%), mp 127–129 °C. IR (neat) 2831, 1647, 1597, 1508, 1450, 1423, 1342, 1292,
1253, 1222, 1172, 1126, 1029, 983, 925, 813, 767, 651, 551, 520 cm−1.1H NMR (CDCl3,
300 MHz): δ 7.99 (2H, d, J = 9.0 Hz), 7.95 (1H, dd, J = 1.8, 9.0 Hz), 7.82 (1H, s), 7.78 (2H,
dd, J = 15.0, 15.0 Hz), 7.60 (4H, dd, J = 8.7, 8.7 Hz), 7.44 (2H, dd, J = 15.0, 15.0 Hz), 6.92
(7H, m), 3.87 (2H, s), 3.84 (6H, s), 3.48 (4H, s), 2.76 (4H, s). 13C NMR (CDCl3, 75 MHz):
δ 188.3, 188.1, 162.1, 161.4, 161.3, 153.4, 143.6, 143.1, 130.4 (x3), 130.3, 130.1, 130.0
(x2), 129.9 (x3), 129.1, 127.8, 127.6, 120.6, 119.4, 119.2, 116.0, 114.2 (x3), 113.9 (x2),
60.9, 55.3 (x2), 52.0 (x2), 47.1 (x2).FABMS, m/z (% rel. intensity): 589 (37) [M+H]+, 588
(17), 472 (34), 471 (100), 470 (47), 455 (21), 337 (16), 324 (14), 323 (53), 322 (17), 321
(42), 320 (14), 319 (12), 307 (15), 280 (41), 267 (20), 266 (26), 189 (19), 161 (61), 155 (15),
154 (67), 151 (13), 149 (34), 137 (32), 136 (53) 133 (19), 107 (19), 105 (10), 91 (13), 90
(14), 89 (18), 77 (20).HRFABMS m/z calcd for C37H37O5N2, 589.2702; found, 589.2705.
Elemental Analysis: calcd C, 75.49; H, 6.16; N, 4.76; found, C, 74.61; H, 6.19; N, 4.80.
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Compound 1a (704 mg, 2.0 mmol) and 3,4-methylenedioxybenzaldehyde (600 mg, 4.0
mmol) were treated as described above. The crude product was purified by CC eluting with
(i-Pr)2O/MeOH (9:1) to yield 12 (pale yellow solid, 765 mg, 62%), mp 83–85 °C. IR (neat)
3005, 2893, 2831, 1654, 1597, 1492, 1446, 1361, 1307, 1249, 1192, 1111, 1037, 991, 929,
810, 756, 659, 601, 528 cm−1.1H NMR (CDCl3, 300 MHz): δ 7.98 (2H, d, J = 8.7 Hz), 7.93
(1H, dd, J = 2.1, 8.7 Hz), 7.71 (2H, dd, J = 15.6, 15.6 Hz), 7.38 (2H, d, J = 15.6 Hz), 7.14
(4H, m), 6.90 (2H, d, J = 8.7 Hz), 6.82 (4H, m), 6.00 (4H, s), 3.85 (2H, s), 3.47 (4H, s), 2.74
(4H, s). 13C NMR (CDCl3, 75 MHz): δ 188.1, 187.8, 162.2, 153.4, 149.6, 149.5, 148.2,
143.6, 143.1, 130.4 (x2), 130.2, 130.0, 129.7, 129.5, 129.4, 129.0, 124.9, 124.8, 120.7,
119.8, 119.6, 116.0, 113.9 (x2), 108.5 (x2), 106.5 (x2), 101.4 (x2), 61.0, 52.0 (x2), 47.2
(x2). FABMS, m/z (% rel. intensity): 617 (18) [M+H]+, 616 (11), 486 (17), 485 (52), 484
(32), 483 (15), 337 (33), 335 (22), 307 (22), 294 (21), 281 (15), 280 (14), 189 (12), 175 (30),
165 (16), 155 (24), 154 (100), 152 (11), 149 (28), 138 (27), 137 (49), 136 (75), 135 (12),
120 (14), 107 (27), 91 (15), 90 (17), 89 (27), 77 (22).HRFABMS m/z calcd for C37H33O7N2,
616.2288; found, 616.2286. Elemental Analysis: calcd C, 72.07; H, 5.23; N, 4.54; found, C,
71.85; H, 5.20; N, 4.52.
4.3.11. (E)-3-(2-Chlorophenyl)-1-(4-(4-(5-((E)-3-(2-chlorophenyl)acryloyl)-2-
hydroxybenzyl)piperazin-1-yl)phenyl)prop-2-en-1-one (13)—Compound 1a (704
mg, 2.0 mmol) and 2-chlorobenzaldehyde (560 mg, 4.0 mmol) were treated as described
above. The crude product was purified by CC eluting with benzene/acetone (9:1) to yield 13
(pale yellow solid, 680 mg, 57%), mp 34–36 °C. IR (neat) 3012, 2831, 1654, 1597, 1442,
1388, 1319, 1276, 1222, 1192, 1122, 1029, 995, 925, 864, 825, 756, 667, 570 cm−1.1H
NMR (CDCl3, 300 MHz): δ 8.31 (2H, dd, J = 15.6, 15.6 Hz), 7.99 (2H, d, J = 9.0 Hz), 7.94
(1H, dd, J = 2.1, 9.0 Hz), 7.80 (2H, d, J = 15.0 Hz), 7.73 (2H, m), 7.54 (4H, m), 7.31 (4H,
m), 6.91 (2H, d, J = 9.0 Hz), 3.87 (2H, s), 3.44 (4H, s), 2.76 (4H, s). 13C NMR (CDCl3, 75
MHz): δ 188.3, 187.8, 162.5, 153.6, 139.6, 139.1, 135.3, 135.2, 133.5, 133.3, 131.0, 130.9
(x3), 130.5, 130.2, 130.0, 129.6, 128.6, 127.6 (x3), 127.0, 126.9, 124.6, 124.5, 120.8, 116.1,
113.9 (x2), 61.0, 52.0 (x2), 47.1 (x2).FABMS, m/z (% rel. intensity): 597 (39) [M+H]+, 596
(22), 459 (8), 327 (17), 325 (12), 307 (21), 289 (12), 271 (13), 165 (20), 155 (27), 154 (100),
139 (11), 138 (26), 137 (54), 136 (64), 120 (11), 107 (19), 106 (7), 91 (11), 89 (17), 77
(15).HRFABMS m/z calcd for C35H31O3N2Cl2, 597.1712; found, 597.1714. Elemental
Analysis: calcd C, 70.35; H, 5.06; N, 4.69; found, C, 70.03; H, 5.65; N, 4.40.
4.3.12. (E)-3-(2,4-Dichlorophenyl)-1-(4-(4-(5-((E)-3-(2,4-
dichlorophenyl)acryloyl)-2-hydroxybenzyl)piperazin-1-yl)phenyl)prop-2-en-1-
one (14)—Compound 1a (704 mg, 2.0 mmol) and 2,4-chlorobenzaldehyde (692 mg, 4.0
mmol) were treated as described above. The crude product was purified by CC eluting with
benzene/acetone (9:1) to yield 14 (pale yellow solid, 710 mg, 53%), mp 41–43 °C. IR (neat)
3417, 2843, 2349, 1651, 1597, 1527, 1469, 1384, 1346, 1315, 1222, 1192, 1103, 1049, 995,
925, 813, 732, 671 cm−1.1H NMR (CDCl3, 300 MHz): δ 8.04 (2H, dd, J 15.6, 15.6 Hz),
7.99 (2H, d, J = 9.0 Hz), 7.93 (1H, dd, J = 2.1, 9.0 Hz), 7.81 (1H, d, J = 1.8 Hz), 7.68 (2H,
d, J = 9.0 Hz), 7.47 (2H, dd, J = 15.0, 15.0 Hz), 7.45 (1H, s), 7.36 (1H, s), 7.29 (2H, s), 6.92
(3H, d, J = 9.0 Hz), 3.89 (2H, s), 3.47 (4H, s), 2.78 (4H, s). 13C NMR (CDCl3, 75 MHz): δ
188.0, 187.6, 162.6, 153.7, 138.4, 137.9, 136.2, 136.0, 135.9, 135.8, 132.1, 132.0, 130.7
(x2), 130.6, 130.1, 130.0, 129.5, 128.5, 128.4 (x2), 128.3 (x2), 127.4 (x2), 124.9, 124.8,
120.9, 116.2, 113.9, 61.1, 52.1 (x2), 47 (x2). FABMS, m/z (% rel. intensity): 667 (13), 666
(10), 665 (11), [M+H]+, 307 (27), 289 (12), 199 (5), 155 (25), 154 (100), 153 (5), 139 (10),
138 (27), 137 (55), 136 (66), 120 (10), 107 (17), 90 (10), 9 (14), 77 (12).HRFABMS m/z
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calcd for C35H29O3N2Cl4, 665.0932; found, 665.0929. Elemental Analysis: calcd C, 63.08;
H, 4.23; N, 4.20; found, C, 62.79; H, 4.44; N, 4.00.
4.3.13. (E)-1-(4-Hydroxy-3-methoxy-5-((4-(4-((E)-3-(thiophen-2-
yl)acryloyl)phenyl)piperazin-1-yl)methyl)phenyl)-3-(thiophen-2-yl)prop-2-en-1-
one (15)—Compound 2a (955 mg, 2.5 mmol) and 2-thiophenecarboxaldehyde (560 mg,
5.0 mmol) were treated as described above. The crude product was purified by CC eluting
with (i-Pr)2O/MeOH (9:1) to yield 15 (pale yellow solid, 1.02 gm, 72%), mp 109–111 °C.
IR (neat) 3082, 2831, 1647, 1597, 1523, 1454, 1419, 1350, 1288, 1226, 1192, 1165, 1033,
999, 968, 921, 817, 709, 567 cm−1.1H NMR (CDCl3, 300 MHz): δ 7.99 (2H, d, J = 9.0 Hz),
7.91 (2H, dd, J = 15.3, 15.3 Hz), 7.57 (1H, s), 7.39 (3H, m), 7.33 (2H, dd, J = 15.3, 15.3
Hz), 7.32 (2H, d, J = 3.6 Hz), 7.06 (2H, d, J = 4.2 Hz), 6.91 (2H, d, J = 9.0 Hz), 3.97 (3H,
s), 3.94 (2H, s), 3.44 (4H, s), 2.78 (4H, s). 13C NMR (CDCl3, 75 MHz): δ 187.5, 187.3,
153.4, 151.9, 148.1, 140.5, 140.4, 136.2, 135.7, 131.7, 131.4, 130.4 (x2), 129.5, 128.7,
128.3, 128.2, 128.1 (x2), 122.4, 120.5, 120.1, 119.9, 113.8 (x2), 110.8, 60.8, 55.9, 51.9 (x2),
47.1 (x2). FABMS, m/z (% rel. intensity): 571 (24) [M+H]+, 570 (15), 477 (20), 476 (13),
307 (25), 299 (13), 297 (11), 289 (15), 273 (11), 256 (11), 155 (25), 154 (100), 139 (11),
138 (29), 137 (61), 136 (70), 120 (11), 107 (20), 91 (11), 90 (13), 89 (18), 77
(16).HRFABMS m/z calcd for C32H31O4N2S2, 571.1725; found, 571.1726. Elemental




yl)prop-2-en-1-one (16)—Compound 2a (955 mg, 2.5 mmol) and 3-methyl-2-
thiophenecarboxaldehyde (630 mg, 5.0 mmol) were treated as described above. The crude
product was purified by CC eluting with benzene/acetone (9:1) to yield 16 (pale yellow
solid, 975 gm, 65%), mp 76–78 °C. IR (neat) 2831, 1647, 1597, 1523, 1450, 1388, 1346,
1288, 1222, 1188, 1037, 825, 752, 524 cm−1.1H NMR (DMS0-d6, 300 MHz): δ 7.96 (2H, d,
J = 9.0 Hz), 7.86 ( 2H, dd, J = 15.3, 15.3 Hz), 7.65 (3H, m), 7.53 (1H, s), 7.40 (2H, dd, J =
15.0, 15.0 Hz), 7.02 (4H, m), 3.88 (3H, s), 3.79 (2H, s), 3.42 (4H, s), 2.64 (4H, s), 2.36 (6H,
s). 13C NMR (DMSO-d6, 75 MHz): δ 186.3, 185.7, 153.4, 151.1, 147.4, 141.8, 141.6, 133.9,
133.8, 133.6, 133.1, 131.2 (x2), 130.0 (x2), 128.5, 127.6, 127.4, 127.3, 123.1, 121.4, 119.3,
119.2, 113.3 (x2), 110.1, 58.1, 55.6, 51.6 (x2), 46.4 (x2), 13.8 (x2). FABMS, m/z (% rel.
intensity): 599 (87) [M+H]+, 598 (55), 597 (22), 475 (22), 394 (29), 393 (49), 391 (35), 323
(20), 322 (68), 313 (38), 311 (33), 307 (16), 289 (15), 288 (13), 287 (34), 270 (29), 189 (20),
154 (100), 151 (66), 149 (93), 137 (58), 123 (18), 113 (16), 109 (24), 108 (11), 107 (34), 95
(39), 91 (41), 83 (33), 81 (38), 77 (33), 69 (44).HRFABMS m/z calcd for C34H35O4N2S2,
599.2038; found, 599.2038. Elemental Analysis: calcd C, 68.20; H, 5.72; N, 4.68; S, 10.7;
found, C, 67.86; H, 6.03; N, 4.34; S, 10.65.
4.3.15. (E)-1-(4-(4-(5-Cinnamoyl-2-hydroxy-3-methoxybenzyl)piperazin-1-
yl)phenyl)-3-phenylprop-2-en-1-one (17)—Compound 2a (955 mg, 2.5 mmol) and
benzaldehyde (530 mg, 5.0 mmol) were treated as described above. The crude product was
purified by CC eluting with (i-Pr)2O/MeOH (9:1) to yield 15 (pale yellow solid, 820 mg,
59%), mp 43–45 °C. IR (neat) 3437, 2873, 1651, 1600, 1527, 1492, 1450, 1350, 1222, 1192,
1103, 999, 925, 806, 767, 690, 675, 563 cm−1.1H NMR (CDCl3, 300 MHz): δ 8.01 (2H, d, J
= 9.0 Hz), 7.81 (2H, dd, J = 15.0, 15.0 Hz), 7.65 (5H, m), 7.56 (2H, dd, J = 15.0, 15.0 Hz),
7.42 (7H, m), 6.92 (2H, d, J = 9.0 Hz), 3.98 (3H, s), 3.90 (2H, s), 3.45 (4H, s), 2.77 (4H,
s). 13C NMR (DMSO-d6, 75 MHz): δ 188.2, 188.0, 153.5, 152.0, 148.2, 143.8, 143.3, 135.1,
135.0, 130.6 (x2), 130.3, 130.1, 129.6, 128.8 (x4), 128.3 (x2), 128.2 (x3), 122.6, 121.8,
121.5, 120.0, 113.9 (x2), 111.0, 60.8, 56.0, 52.0 (x2), 47.2 (x2). FABMS, m/z (% rel.
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intensity): 559 (72) [M+H]+, 558 (46), 557 (17), 455 (13), 396 (23), 307 (18), 295 (12), 293
(36), 292 (13), 291 (29), 290 (11), 289 (19), 267 (40), 189 (13), 174 (19), 155 (24), 154
(100), 152 (13), 138 (28), 136 (78), 131 (73), 121 (20), 107 (29), 106 (10), 105 (15), 91 (24),
77 (32).HRFABMS m/z calcd for C36H35O4N2, 559.2597; found, 559.2600. Elemental
Analysis: calcd C, 77.40; H, 6.13; N, 5.01; found, C, 76.81; H, 6.36; N, 4.67.
4.3.16. (E)-1-(4-Hydroxy-3-methoxy-5-((4-(4-((E)-3-(4-
methoxyphenyl)acryloyl)phenyl)piperazin-1-yl)methyl)phenyl)-3-(4-
methoxyphenyl)prop-2-en-1-one (18)—Compound 2a (955 mg, 2.5 mmol) and 4-
methoxybenzaldehyde (680 mg, 5.0 mmol) were treated as described above. The crude
product was purified by CC eluting with benzene/acetone (9:1) to yield 18 (pale yellow
solid, 1.08 gm, 70%), mp 89–91 °C. IR (neat) 2931, 2835, 1651, 1597, 1512, 1454, 1419,
1388, 1346, 1300, 1257, 1168, 1111, 1029, 995, 925, 821, 756, 671, 528 cm−1.1H NMR
(DMS0-d6, 300 MHz): δ 7.97 (2H, d, J = 9.0 Hz), 7.72 (2H, dd, J = 15.6, 15.6 Hz), 7.59
(2H, d, J = 15.6 Hz), 7.56 (3H, m), 7.42 (3H, m), 6.90 (6H, m), 3.95 (3H, s), 3.82 (8H, s),
3.41 (4H, s), 2.75 (4H, s). 13C NMR (DMSO-d6, 75 MHz): δ 188.2, 188.0, 161.4, 161.2,
153.3, 151.7, 148.0, 143.6, 143.1, 130.4 (x2), 130.0 (x2), 129.9 (x2), 129.1, 127.8, 127.6,
122.3, 119.9, 119.4, 119.0, 114.2 (x5), 113.9 (x2), 110.9, 60.9, 56.0, 55.2 (x2), 52.0 (x2),
47.2 (x2). FABMS, m/z (% rel. intensity): 619 (44) [M+H]+, 618 (29), 617 (11), 323 (17),
322 (6), 321 (15), 307 (24), 298 (5), 297 (14), 293 (4), 289 (12), 280 (13), 161 (32), 155
(24), 154 (100), 153 (6), 152 (8), 139 (9), 138 (25), 137 (52), 136 (67), 121 (9), 120 (10),
107 (18), 91 (10), 90 (12), 89 (17), 77 (15).HRFABMS m/z calcd for C38H39O6N2,
619.2808; found, 619.2808. Elemental Analysis: calcd C, 73.77; H, 6.19; N, 4.53; found, C,
73.21; H, 6.37; N, 4.44.
4.3.17. (E)-3-(2-Chlorophenyl)-1-(4-(4-(5-((E)-3-(2-chlorophenyl)acryloyl)-2-
hydroxy-3-methoxybenzyl)piperazin-1-yl)phenyl)prop-2-en-1-one (19)—
Compound 2a (955 mg, 2.5 mmol) and 2-chlorobenzaldehyde (700 mg, 5.0 mmol) were
treated as described above. The crude product was purified by CC eluting with benzene/
acetone (9:1) to yield 20 (pale yellow solid, 925 gm, 59%), mp 42–44 °C. IR (neat) 2873,
1654, 1593, 1450, 1350, 1292, 1222, 1192, 1168, 1107, 1053, 999, 921, 759, 671, 570
cm−1.1H NMR (CDCl3, 300 MHz): δ 8.13 (2H, d, J = 15.6 Hz), 7.97 (2H, d, J = 9.0 Hz),
7.73 (2H, m), 7.57 (1H, d, J = 1.8 Hz), 7.50 (2H, dd, J = 15.3, 15.3 Hz), 7.47 (3H, m), 7.32
(4H, m), 6.90 (2H, d, J = 9.0 Hz), 3.96 (3H, s), 3.85 (2H, s), 3.44 (4H, s), 2.78 (4H, s). 13C
NMR (CDCl3, 75 MHz): δ 188.3, 187.8, 153.5, 152.1, 148.2, 139.6, 139.0, 135.2, 133.5,
133.3, 130.9, 130.7 (x3), 130.1, 129.3 (x2), 127.6 (x3), 127.0, 126.9, 124.6, 124.5, 122.8,
120.0, 113.9 (x3), 111.1, 60.9, 56.0, 52.0 (x2), 47.2 (x2). FABMS, m/z (% rel. intensity):
627 (37) [M+H]+, 626 (23), 329 (10), 327 (20), 325 (16), 307 (18), 301 (20), 289 (12), 284
(12), 167 (11), 165 (29), 155 (27), 154 (100), 139 (13), 138 (30), 137 (61), 136 (74), 120
(14), 107 (23), 105 (10), 91 (15), 90 (14), 89 (20), 77 (17).HRFABMS m/z calcd for
C36H33O4N2Cl2, 627.1817; found, 627.1815. Elemental Analysis: calcd C, 68.09; H, 5.14;
N, 4.46; found, C, 67.87; H, 5.27; N, 4.34.
4.3.18. (E)-1-(4-Hydroxy-3-methoxy-5-((4-(4-((E)-3-(pyridin-2-
yl)acryloyl)phenyl)piperazin-1-yl)methyl)phenyl)-3-(pyridin-2-yl)prop-2-en-1-
one (20)—Compound 2a (955 mg, 2.5 mmol) and 2-pyridinecarboxaldehyde (535 mg, 5.0
mmol) were treated as described above. The crude product was purified by CC eluting with
benzene/acetone (9:1) to yield 19 (pale yellow solid, 1.02 gm, 73%), mp 84–86 °C. IR (neat)
2831, 1658, 1589, 1527, 1492, 1465, 1431, 1330, 1222, 1192, 1165, 995, 921, 783, 748, 667
cm−1.1H NMR (CDCl3, 300 MHz): δ 8.66 (2H, t, J = 4.2 Hz), 8.14 (1H, d, J = 3.0 Hz), 8.06
(2H, d, J = 16.2 Hz), 8.05 (1H, d, J = 4.2 Hz), 7.75 (1H, d, J = 15.6 Hz), 7.73 (1H, d, J =
15.6 Hz), 7.68 (2H, d, J = 1.2 Hz), 7.62 (1H, s), 7.52 (1H, s), 7.45 (2H, m), 7.28 (2H, m),
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6.89 (2H, d, J = 9.0 Hz), 3.96 (3H, s), 3.87 (2H, s), 3.44 (4H, s), 2.76 (4H, s). 13C NMR
(CDCl3, 75 MHz): δ 187.9, 187.8, 153.5, 153.3, 153.1, 152.2, 149.9 (x2), 148.1, 141.6,
141.2, 136.8, 136.7, 130.8 (x2), 129.3, 128.4, 125.4 (x2), 125.1, 124.9, 124.1, 124.0, 123.0,
119.9, 113.7 (x2), 110.8, 60.7, 55.9, 51.9 (x2), 47.0 (x2). FABMS, m/z (% rel. intensity):
561 (77) [M+H]+, 560 (47), 559 (20), 456 (11), 380 (17), 307 (13), 295 (12), 294 (40), 293
(13), 292 (35), 291 (20), 290 (14), 268 (50), 251 (26), 155 (24), 154 (81), 138 (29), 136 (68),
132 (100), 109 (21), 107 (33), 106 (40), 105 (26), 91 (30), 81 (35), 77 (26), 69 (48), 57 (47),
55 (46).HRFABMS m/z calcd for C34H33O4N4, 561.2502; found, 561.2501. Elemental
Analysis: calcd C, 72.84; H, 5.75; N, 9.99; found, C, 72.40; H, 6.07; N, 9.55.
4.3.19. (E)-1-(3-((4-(4-Acetylphenyl)piperazin-1-yl)methyl)-4-hydroxyphenyl)-3-
(1H-pyrrol-2-yl)prop-2-en-1-one (21)—Compound 1 (1.36 g, 10 mmol) and pyrrole2-
carboxaldehyde (950 mg, 10 mmol) were treated as described above for the general
procedure for chalcones to obtain 1b in 82% yield. The crude product was used directly in
the Mannich base reaction. Compound 1b (1.065 g, 5 mmol), 4-piperizinoacetophenone
(1.02 g, 5 mmol) and paraformaldehyde (150 mg, 5 mmol) were treated as described above.
The crude product was purified by CC eluting with hexanes/EtOAc (7:3) to yield 21 (pale
yellow solid, 1.5 gm, 70%), mp 66–68 °C. IR (neat) 1670, 1643, 1597, 1570, 1531, 1450,
1411, 1357, 1284, 1242, 1126, 1029, 975, 821, 752, 686, 605 cm−1.1H NMR (DMS0-d6,
300 MHz): δ 11.64 (1H, s, NH), 7.94 (2H, d, J = 9.0 Hz), 7.79 (2H, dd, J = 8.1, 1.5 Hz),
7.57 (1H, d, J = 15.3 Hz), 7.50 (1H, d, J = 15.3 Hz), 7.09 (1H, s), 7.03 (2H, d, J = 9.0 Hz),
6.87 (1H, d, J = 8.1 Hz), 6.65 (1H, s), 6.20 (1H, s), 3.70 (2H, s), 3.40 (4H,s), 2.61 (4H, s),
2.50 (3H, s). 13C NMR (DMSO-d6, 75 MHz): δ 196.3, 186.2, 161.3, 153.5, 132.7, 130.5,
130.0 (x2), 129.6, 129.3, 128.5, 128.0, 123.6, 122.5, 115.5, 115.3, 114.9, 113.5 (x2), 110.4,
57.4, 51.9 (x2), 46.6 (x2), 26.3. FABMS, m/z (% rel. intensity): 430 (11) [M+H]+, 307 (35),
289 (18), 155 (25), 154 (100), 139 (10), 138 (26), 137 (48), 136 (63), 107 (16), 89
(13).HRFABMS m/z calcd for C26H28O3N3, 430.2131; found, 430.2130. Elemental
Analysis: calcd C, 72.71; H, 6.34; N, 9.78; found, C, 71.94; H, 6.45; N, 9.52.
4.3.20. (E)-1-(3-((4-(4-Acetylphenyl)piperazin-1-yl)methyl)-4-hydroxyphenyl)-3-
(1-methyl-1H-pyrrol-2-yl)prop-2-en-1-one (22)—Compound 1 (1.36 gm, 10 mmols)
and N-methyl-pyrrole-2-carboxaldehyde (1.09 g, 10 mmol) were treated as described above
in the synthesis of chalcones, to obtain 1c in 79% yield. The crude product was used directly
in the Mannich base reaction. Compound 1c (1.14 g, 5 mmol), 4-piperizinoacetophenone
(1.02 g, 5 mmol), and paraformaldehyde (150 mg, 5 mmol) were treated as described above.
The crude product was purified by CC eluting with (i-Pr)2O/MeOH (9:1) to yield 22 (pale
yellow solid, 1.45 gm, 65%), mp 166–168 °C. IR (neat) 3390, 2873, 1597, 1527, 1350,
1284, 1192, 1103, 1037, 925, 806, 675 cm−1.1H NMR (DMS0-d6, 300 MHz): δ 7.99 (2H, d,
J = 9.0 Hz), 7.83 (1H, s), 7.79 (1H, s), 7.64 (1H, d, J = 15.0 Hz), 7.51 (1H, d, J = 15.0 Hz),
7.02 (3H, d, J = 9.0 Hz), 6.99 (1H, d, J = 3.3 Hz), 6.88 (1H, d, J = 9.0 Hz), 6.16 (1H, t, J =
3.3 Hz), 3.76 (3H, s), 3.72 (2H, s), 3.40 (4H, s), 2.62 (4H, s), 2.49 (3H, s). 13C NMR
(DMSO-d6, 75 MHz): δ 196.1, 186.0, 161.2, 153.4, 130.5, 130.3, 130.1 (x2), 129.8, 129.5,
128.4, 128.0, 127.8, 122.5, 116.2, 115.1, 113.3 (x2), 112.4, 109.0, 57.3, 51.9 (x2), 46.6 (x2),
33.9, 26.2. FABMS, m/z (% rel. intensity): 444 (66) [M+H]+, 443 (35), 442 (15), 337 (12),
307 (21), 296 (12), 294 (13), 289 (11), 253 (12), 239 (13), 155 (25), 149 (24), 139 (11), 138
(28), 137 (53), 136 (71), 134 (40), 120 (14), 107 (25), 106 (14), 90 (15), 89 (21), 77
(19).HRFABMS m/z calcd for C27H30O3N3, 444.2287; found, 444.2287. Elemental
Analysis: calcd C, 73.11; H, 6.59; N, 9.47; found, C, 72.63; H, 6.69; N, 9.47.
4.3.21. (E)-1-(3-((4-(4-Acetylphenyl)piperazin-1-yl)methyl)-4-hydroxy-5-
methoxyphenyl)-3-(pyridin-3-yl)prop-2-en-1-one (23)—Compound 2 (1.66 g, 10
mmol) and 3-pyridinecarboxaldehyde (1.07 g, 10 mmol) were treated as described above in
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the general procedure for chalcones to obtain 2b in 75% yield. The crude product was used
directly in the Mannich base reaction. Compound 2b (1.28 g, 5.0 mmol), 4-
piperizinoacetophenone (1.02 g, 5.0 mmol), and paraformaldehyde (150 mg, 5.0 mmol)
were treated as described above. The crude product was purified by CC eluting with (i-
Pr)2O/MeOH (9:1) to yield 23 (pale yellow solid, 1.45 gm, 62%), mp 146–148 °C. IR (neat)
2831, 1658, 1589, 1489, 1450, 1411, 1357, 1300, 1222, 1192, 1145, 1107, 1083, 999, 921,
806, 752, 678, 628, 563 cm−1.1H NMR (CDCl3, 300 MHz): δ 8.85 (1H, s), 8.60 (1H, s),
7.99 (2H, d, J = 9.0 Hz), 7.93 (1H, d, J = 7.5 Hz), 7.75 (1H, d, J = 15.6 Hz), 7.60 (1H, d, J =
15.6 Hz), 7.47 (1H, d, J = 1.2 Hz), 7.35 (1H, m), 7.32 (1H, s), 6.91 (2H, d, J = 9.0 Hz), 3.93
(3H, s), 3.85 (2H, s), 3.45 (4H, s), 2.76 (4H, s), 2.54 (3H, s). 13C NMR (CDCl3, 75 MHz): δ
196.5, 187.3, 153.7, 151.9, 150.7, 149.7, 147.9, 139.4, 134.4, 130.7 (x3), 128.8, 128.4,
123.6, 122.6, 119.8, 113.9 (x3), 110.5, 60.9, 56.0, 52.0 (x2), 47.2 (x2), 26.1.FABMS, m/z (%
rel. intensity): 472 (18) [M+H]+, 392 (13), 391 (46), 307 (11), 167 (25), 155 (25), 154 (87),
152 (12), 150 (17), 149 (100), 139 (17), 138 (35), 137 (64), 136 (66), 124 (10), 121 (15),
120 (14), 113 (23), 107 (28), 97 (22), 95 (29), 91 (23), 89 (18), 77 (18), 69 (40), 57 (51), 55
(38).HRFABMS m/z calcd for C28H30O4N3, 472.2236; found, 472.2239. Elemental
Analysis: calcd C, 71.32; H, 6.20; N, 8.91; found, C, 70.43; H, 6.16; N, 8.74.
4.4. Measurement of NADPH oxidase activity
NADPH oxidase activity was measured as described previously.10 Test compounds were
added to the wells of a bioluminescence plate and incubated with 50 µg of cell homogenate
for 20 min at 37 °C in the dark. O2 production was stimulated with 200 µM NADPH, and
the chemiluminescence was monitored for 30 min, after which the AUC (area under the
curve) was calculated to represent reactive oxygen species production (NADPH activity).
4.5. Measurement of 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical-scavenging capacity
The DPPH radical –scavenging capacity assay was performed in our previous report.20 The
DPPH solution (200 µL, at a final concentration of 200 µM in MeOH) was added to 10 µL
of diluted drugs in each well of a 96-well microplate, and the resulting solution was allowed
to react for 30 min in the dark at rt. The absorbance (A517 OD units) is defined as the
optical density (OD) measured at 517 nm caused by the DPPH radical as determined using a
Power Wave™ XS (BioTek) microplate-spectrophotometer. The radical-scavenging
capacity is expressed as the change in the OD517 over 30 min (Δ A517 OD units/30 min).
The antioxidant, Trolox (OXIS, USA), was included as a reference compound.
4.6. Microglial cell culture and measurement of nitric oxide (NO)
A murine microglial cell line (BV2) was cultured in Dulbecco’s modified Eagle medium
(DMEM; Gibco, USA) supplemented with 5% fetal bovine serum (Hyclone, USA). The
production of NO was determined by measuring the accumulation of nitrite in the culture
medium 24 h after stimulation with LPS (0.5 µg/mL) by the Griess reagent as in our
previous report.10
4.7. Western immunoblot analysis of iNOS and NFκB p65
Equal amounts of protein (50 µg) at different time points from 0.5 µg/mL LPS-treated
samples in the absence or presence of compound 4 or 11 (0.5~1.0 µM) were subjected to
sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) and electro-
transferred to a hydrophobic polyvinylidene difluoride (PVDF) membrane. After blocking
with 5% nonfat milk in phosphate buffered saline (PBS) containing 0.05% Tween 20
(PBST) at 4 °C for 1 h, the membrane was washed three times with PBST and incubated
overnight at 4 °C with an antibody against iNOS (BD Pharmingen, BD Biosciences, San
Diego, CA, USA) and NFκB p65 (BD Transduction Laboratories, BD Biosciences, San
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Diego, CA, USA) at a properly titrated dilution (1:1000~2500). After additional washes with
PBST, the membrane was incubated with a second antibody IgG conjugated with
horseradish peroxidase (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h at rt. The
immunoblot on the membrane was visible after development with an enhanced
chemiluminescence (ECL) system (Perkin-Elmer, Wellesley, MA, USA) and was
quantitated using an image program21 (Multi Gauge v2.2 software, Fujifilm, Tokyo, Japan).
4.8. Cytotoxic activity assay
All stock cultures were grown in T-25 flasks. Freshly trypsinized cell suspensions were
seeded in 96-well microtiter plates at densities of 1500–7500 cells per well with compounds
added from DMSO-diluted stock. After 3 days in culture, attached cells were fixed with cold
50% trichloroacetic acid and then stained with 0.4% sulforhodamine B. The absorbance at
562 nm was measured using a microplate reader after solubilizing the bound dye. The mean
EC50 is the concentration of agent that reduces cell growth by 50% under the experimental
conditions and is the average from at least three independent determinations that were
reproducible and statistically significant. The following human tumor cell lines were used in
the assay: A549 (non small cell lung cancer), HCT-8 (ileocecal), KB (nasopharyngeal
carcinoma) and DU145 (prostate cancer). All cell lines were obtained from the Lineberger
Comprehensive Cancer Center (UNC-CH) or from ATCC (Rockville, MD) and were
cultured in RPMI-1640 medium supplemented with 25 µM HEPES, 0.25% sodium
bicarbonate, and 10% fetal bovine serum.22
4.9. Cell culture
Human colon adenocarcinoma cell line HT-29 was obtained from the American Type
Culture Collection. Cells were maintained in RPMI-1640 containing 100 M)mL/L FBS with
100,000 U/L penicillin and 100 mg/L streptomycin.
4.10. MTT assay
HT-29 cells were plated onto 96-well plates and exposure to compound 23 as detailed
concentration in respective experiments for 24 and 48 h. Then, MTT was added to each well
then incubated for an additional 4 h in the dark at 37 °C. The medium was then aspirated
from the wells and the blue formazon product was dissolved in 100 µL of DMSO. The
plates were analyzed at O.D.570 nm using a spectrophotometric plate reader (Bio-Rad,
Tokyo, Japan). Each data point was replicated in triplicate. Percentage of cell viability was
calculated as (O.D. of drug-treated sample/O.D. of none treated sample)×100%.
4.11. DAPI staining
After compound 23 (30 µM) treatment, cells were fixed in 4% paraformaldehyde for 30 min,
and incubated with 1 µg/mL of DAPI staining solution for 30 min in the dark. The apoptotic
cells were observed through fluorescence microscopy (Zeiss, Oberköchen, Germany).
4.12. Assessment for apoptosis
The induction of cell apoptosis was assayed by Tdt-mediated deoxyuridine triphosphate nick
end labeling (TUNEL) staining. Cells were seeded into each well of 6-well plate. After the
compound 23 time-dependent 24 and 48 h treatments, cells were harvested and were then
immediately incubated with working strength terminal deoxynucleotidyl transferase (Tdt)
enzyme in a humidified chamber at 37 °C for 1 h. Cells were immersed in stop/wash buffer
and gently rinsed with PBS. FITC-labeled antidigoxigenin conjugate was then applied to
cells and incubated at 37 °C for 30 min in the dark. Cells were washed with PBS then
TUNEL positive cells were determined by flow cytometry (FACSCalibur, Becton
Dickinson).
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Proteins (30 µg) were resolved on SDS-PAGE and transferred onto a polyvinylidene
fluoride membrane (PVDF; Millipore). After blocking, the blots were incubated with an
appropriate dilution of specific monoclonal antibodies for Fas/CD95, FADD, cytochrome c,
Apaf-1, pro-caspase-9, pro-caspase-8, caspase-3, AIF, Endo G, Bax, Bcl-2, t-Bid (Santa
Cruz Biotechnology, USA) for 12 h. Blots were washed three times and then incubated with
horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology, USA).
The specific protein was detected by using enhanced chemiluminescence kits (Amersham,
ECL Kits) (30).
4.14. Caspase activity assay
HT-29 cells were collected in lysis buffer (50 mM Tris-HCl, 1 mM EDTA, 10 mM EGTA,
10 mM digitonin and 2 mM DTT) on ice for 10 min. The lysates were centrifuged at
15,000×g at 4 °C for 10 min. Cell lysates (50 µg protein) were incubated with caspase-3, -9
and -8 specific substrates (Ac-DEVD-pNA, Ac-LEHD-pNA, and Ac-IETD-pNA) with
reaction buffer in a 96-well plate at 37 °C for 1 h. The caspase activity was determined by
measuring OD 405 of the released pNA.
4.15. Statistical analysis
Student’s t-test was used to analyze differences between compound 23 treated and control
groups. *p<0.05, **p<0.01, ***p<0.001
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Effects of compounds 4 and 11 on the LPS-induced iNOS expression and nuclear
translocation of NF-κBp65 in murine microglial cells. Representative immunoblots of iNOS
expression and nuclear (N) translocation of NF-κB p65 [p65(N)] from cytosol [p65(C)] in
microglial cells receiving water only (control), 0.5 µg/mL LPS (L) for 2 h, or 0.5 µg/mL
LPS plus 0.5–1.0 µM of compound 4 or 11 (L+cpd4 or L+cpd11). The β-actin was included
as a reference for protein normalization. Similar results were observed at least in three
independent experiments.
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Effects of compound 23 on cell viability of human colon adenocarcinoma cell line HT-29.
Cells were treated with 0, 10, 20, 30, 40 and 50 µM of compound 23 for 24 h by MTT assay
(A). Cells were treated with 30 µM of compound 23 for 12, 24, 48 and 72h by MTT assay
(B) Results are presented as mean±SD. The experiments were done in triplicate. ***p<0.001
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Effects of compound 23 on cell morphological changes (A), and DNA condensation by
DAPI staining (B) in human colon adenocarcinoma cell line HT-29. After incubation with
compound 23 (30 and 50 µM) for 24 and 48 h, cells exhibited nuclear shrinkage and
chromatin condensation (A). DNA condensation was detected by DAPI staining (B). Cells
were examined and photographed under fluoresce microscopy (×200) as described in
Materials and Methods.
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Effects of compound 23 on DNA fragmentation in human colon adenocarcinoma cell line
HT-29. HT-29 cells were treated with compound 23 (30 µM) for 24 and 48h, then cells were
stained with TUNEL and analyzed by FACScan flow cytometry. The experiments were
done in triplicate. ***p<0.001
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Effects of compound 23 on caspase-3, caspase-8 and caspase-9 activity in human colon
adenocarcinoma cell line HT-29 (A) and effects of caspase-3, caspase-8, and caspase-9
inhibitors on cell viability in compound 23-treated HT-29 cells (B). Cells were pretreated
with the caspase-3 inhibitor (Z-DEVE-FMK), caspase-8 inhibitor (Z-IETD-FMK) and
caspase-9 inhibitor (Z-LEHD-FMK) for 1 hour and then treated with 30 µM of compound
23 for 24 h. The total cell extracts were incubated with caspase-3, caspase-8, and caspase-9
specific substrates, respectively (Ac-DEVD-pNA, Ac-LEHD-pNA, and Ac-IETD-pNA).
The release of pNA was measured at 405 nm by a spectrophotometer. For cell viability
assay, cells were pretreated with the caspase-3, caspase-8 and caspase-9 inhibitor for 1 h and
then treated with 30 µM of compound 23 for 24 h by MTT assay. The experiments were
done in triplicate. *p<0.05, **p<0.01, ***p<0.001
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Effects of compound 23-induced apoptotic relative protein levels on HT-29 cells. Western
blotting analysis for (A) Fas/CD95 and FADD; (B) cytosolic cytochrome c, Apaf-1, AIF and
Endo G; (C) pro-caspase-8, pro-caspase-9 and caspase-3; (D) Bax, Bcl-2 and t-Bid protein
levels in compound 23 treated HT-29 cells. For Western blotting analysis, total or cytosolic
protein extracts were analyzed by immunoblotting.
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A proposed model for the apoptosis signaling pathways in 23-treated HT-29 cells.
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(a) Reagents and conditions: 4-piperizino acetophenone, paraformaldehyde, EtOH reflux at
120 °C in 18–22 h
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(a) for 1b from 1, pyrrole-2-carboxaldehyde, MeOH, 30% KOH, rt, 24 h. for 1c from 1, N-
methylpyrrole-2-carboxaldehyde, MeOH, 30% KOH, rt, 24 h.
(b) 4-piperizino acetophenone, paraformaldehyde, EtOH reflux at 120 °C in 18–22 h.
(c) for 2b from 2, 3-pyridinecarboxaldehyde, MeOH, 30% KOH, rt, 24 h.
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Table 1
Summary of the effects of 1–23 on NOS activity in murine microglial cellsa,b
compound IC50 (µM) compound IC50 (µM)
1a 6.6 ± 1.3* 13 30.5 ± 11.4
2a 15.9 ± 1.5 14 25.7 ± 4.6
3 1.4 ± 0.2 15 2.7 ± 0.3
4 0.3 ± 0.0 16 3.1 ± 0.1
5 1.7 ± 0.2 17 2.1 ± 0.4
6 1.9 ± 0.0 18 3.5 ± 0.8
7 7.5 ± 1.6 19 10.9 ± 2.8
8 2.4 ± 0.2 20 1.6 ± 0.3
9 1.2 ± 0.4 21 1.7 ± 0.3
10 2.8 ± 0.5 22 1.9 ± 0.3
11 0.5 ± 0.0 23 3.5 ± 0.4
12 2.1 ± 0.2 L-NAME 18.9 ± 3.2
a
NOS activity was measured by NO production in the presence of 1–50 µM of drug. DPI (diphenyleneiodonium, a NOX inhibitor) was included as
a positive control. Data were calculated as 50% inhibitory concentration (IC50) and expressed as means ± SEM from 3 to 6 experiments performed
on different days using microglial cells from different passages.
*
P < 0.05 as compared with relative positive controls, respectively.
b
Compounds were also tested in NOX and DPPH assays, but none of the compounds were active. NOX activity was measured by ROS production,
and DPI (a NOX inhibitor) was included as positive control (IC50 0.4 ± 0.2 µM). For the DPPH assay, Trolox (an antioxidant) was the positive
control (IC50 36.0 ± 3.5 µM)













Vijaya Bhaskar Reddy et al. Page 28
Table 2
Cytotoxic activity data for 1a–23a
Cmpd GI50 (µM)
KB A549 HCT-8 DU145
3 1.23 1.08 1.26 1.25
4 1.66 1.47 1.40 2.19
6 >37.00 >37.00 >37.00 29.20
17 >35.80 >35.80 25.80 >35.80
20 3.98 1.00 0.70 1.30
21 19.00 20.10 24.70 17.90
22 39.10 31.20 >45.10 >45.10
23 13.10 9.77 11.25 9.98
Paclitaxel 5.16 nM 7.6 nM >100 nM 5.23 nM
a
Compounds that are not shown did not reach 50% inhibition at 20 µg/mL and are considered inactive.
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